On Friday, Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), added 0.37% and closed at $13.40 in the last trading session. The last trading range of the stock ranges between $13.19 and $13.54. The company’s Market capitalization is $2.49 Billion with the total Outstanding Shares of 192.71 million. During the 52-week trading session the minimum price at which share price traded, registered at $4.37 and reached to max level of $14.26. ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, the European Union, Australia, Switzerland, Israel, and Canada. The company also develops Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for the treatment of various patients with a form of non-small cell lung cancer; and AP32788, for treating non-small cell lung cancer and various other solid tumors. It markets and sells Iclusig through specialty pharmacy in the United States.
Hess Corp. (NYSE:HES), dropped -1.10% and closed at $53.07 in the last trading session. The last trading range of the stock ranges between $53.05 and $54.16. The company’s Market capitalization is $16.68 Billion with the total Outstanding Shares of 316.67 million. During the 52-week trading session the minimum price at which share price traded, registered at $32.40 and reached to max level of $64.08. Hess Corporation (HES) declared recently the consideration to be paid in the formerly declared cash tender offer (the “Maximum Tender Offer”) to purchase up to about $324.0 million (the “Aggregate Maximum Repurchase Amount”) of the following series of notes issued by Hess (the “Notes”):
7.875% Notes due 2029;
7.300% Notes due 2031; and
7.125% Notes due 2033.
The Maximum Tender Offer was made following the terms and conditions set forth in the offer to purchase dated September 19, 2016 (the “Offer to Purchase”).
On the otherhand AstraZeneca plc (ADR)(NYSE:AZN), jumped 0.09% and closed at $32.29 in the last trading session. The last trading range of the stock ranges between $32.00 and $32.35. The company’s Market capitalization is $82.39 Billion with the total Outstanding Shares of 1.26 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $26.97 and reached to max level of $35.04. AstraZeneca recently declared data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg contrast to anastrozole 1mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.1 The primary endpoint was PFS and the FALCON trial enrolled 462 patients.
The results, declared at the 2016 European Society for Medical Oncology (ESMO) Congress, show that the median PFS was 2.8 months longer with fulvestrant than anastrozole (Hazard ratio 0.797; 95% confidence interval: 0.637-0.999; p=0.0486). The median PFS was 16.6 months in the fulvestrant arm, contrast with 13.8 months in the anastrozole arm.1 Aromatase inhibitors, such as anastrozole, are the current standard of care in 1st line treatment for postmenopausal women with hormone-receptor positive (HR+) advanced breast cancer.